Rebecca Mercieca-Bebber1,2, Julie Rouette3, Melanie Calvert4, Madeleine T King5,6, Lori McLeod7, Patricia Holch8,9, Michael J Palmer3, Michael Brundage3. 1. Central Clinical School, Sydney Medical School, University of Sydney, Quality of Life Office, Level 6 North, Chris O'Brien Lifehouse C39Z, Sydney, NSW, 2006, Australia. Rebecca.Mercieca@sydney.edu.au. 2. Psycho-oncology Co-operative Research Group, School of Psychology, University of Sydney, Sydney, NSW, 2006, Australia. Rebecca.Mercieca@sydney.edu.au. 3. Cancer Care and Epidemiology, Cancer Research Institute, Queen's University, Kingston, ON, K7L 3N6, Canada. 4. Centre for Patient Reported Outcomes Research, Institute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK. 5. Central Clinical School, Sydney Medical School, University of Sydney, Quality of Life Office, Level 6 North, Chris O'Brien Lifehouse C39Z, Sydney, NSW, 2006, Australia. 6. Psycho-oncology Co-operative Research Group, School of Psychology, University of Sydney, Sydney, NSW, 2006, Australia. 7. RTI Health Solutions, Research Triangle Park, NC, University of North Carolina, Chapel Hill, NC, 27709, USA. 8. Psychology, School of Social Sciences, Faculty of Health and Social Sciences, Leeds Beckett University, City Campus, Leeds, LS1 3HE, UK. 9. Patient Reported Outcomes Research Group, Leeds Institute of Cancer Studies and Pathology, Bexley Wing, St James's Hospital, University of Leeds, Beckett Street, Leeds, LS9 7TF, UK.
Abstract
PURPOSE: This study assessed the uptake of the CONsolidated Standards of Reporting Trials (CONSORT)-Patient-Reported Outcomes (PRO) statement; determined if use of CONSORT-PRO was associated with more complete reporting of PRO endpoints in randomised controlled trials (RCTs) and identified the extent to which high-impact journals publishing RCTs with PRO endpoints endorse CONSORT-PRO. METHODS: CONSORT-PRO citations were identified by systematically searching Medline, EMBASE and Google from 2013 (year CONSORT-PRO released) to 17 December 2015. RCTs that cited CONSORT-PRO (cases) were compared to a comparable control sample of RCTs in terms of adherence to CONSORT-PRO using t tests. General linear models assessed the relationship between CONSORT-PRO score and key, pre-specified variables. The 100 highest-impact journals that published RCTs with PRO endpoints (2014-2015) were identified via a systematic Medline search. Instructions for authors were reviewed to determine whether journals endorsed CONSORT-PRO. RESULTS: Total CONSORT-PRO scores ranged from 47 to 100% for cases and 25-96% for controls. Cases had significantly higher total CONSORT-PRO scores compared to controls: t = 2.64, p = 0.01. 'Citing CONSORT-PRO', 'journal endorsing CONSORT-PRO' and 'dedicated PRO paper' were significant predictors of higher CONSORT-PRO adherence score: R 2 = 0.48, p < 0.001. 11/100 top-ranked journals endorsed CONSORT-PRO in their instructions to authors, seven of these journals published RCTs included as cases in this study. CONCLUSION: This study demonstrated improved PRO reporting associated with journal endorsement and author use of the CONSORT-PRO extension. Despite growing awareness, more work is needed to promote appropriate use of CONSORT-PRO to improve completeness of reporting; in particular, stronger journal endorsement of CONSORT-PRO.
PURPOSE: This study assessed the uptake of the CONsolidated Standards of Reporting Trials (CONSORT)-Patient-Reported Outcomes (PRO) statement; determined if use of CONSORT-PRO was associated with more complete reporting of PRO endpoints in randomised controlled trials (RCTs) and identified the extent to which high-impact journals publishing RCTs with PRO endpoints endorse CONSORT-PRO. METHODS: CONSORT-PRO citations were identified by systematically searching Medline, EMBASE and Google from 2013 (year CONSORT-PRO released) to 17 December 2015. RCTs that cited CONSORT-PRO (cases) were compared to a comparable control sample of RCTs in terms of adherence to CONSORT-PRO using t tests. General linear models assessed the relationship between CONSORT-PRO score and key, pre-specified variables. The 100 highest-impact journals that published RCTs with PRO endpoints (2014-2015) were identified via a systematic Medline search. Instructions for authors were reviewed to determine whether journals endorsed CONSORT-PRO. RESULTS: Total CONSORT-PRO scores ranged from 47 to 100% for cases and 25-96% for controls. Cases had significantly higher total CONSORT-PRO scores compared to controls: t = 2.64, p = 0.01. 'Citing CONSORT-PRO', 'journal endorsing CONSORT-PRO' and 'dedicated PRO paper' were significant predictors of higher CONSORT-PRO adherence score: R 2 = 0.48, p < 0.001. 11/100 top-ranked journals endorsed CONSORT-PRO in their instructions to authors, seven of these journals published RCTs included as cases in this study. CONCLUSION: This study demonstrated improved PRO reporting associated with journal endorsement and author use of the CONSORT-PRO extension. Despite growing awareness, more work is needed to promote appropriate use of CONSORT-PRO to improve completeness of reporting; in particular, stronger journal endorsement of CONSORT-PRO.
Entities:
Keywords:
CONSORT-PRO; Patient-reported outcome; Quality of Life; Reporting standards
Authors: Michael Brundage; Brenda Bass; Judith Davidson; John Queenan; Andrea Bezjak; Jolie Ringash; Anna Wilkinson; Deb Feldman-Stewart Journal: Qual Life Res Date: 2010-11-26 Impact factor: 4.147
Authors: Janet P Edwards; Navjit Dharampal; Wiley Chung; Mantaj S Brar; Chad G Ball; Jonathan Seto; Sean C Grondin Journal: Eur J Cardiothorac Surg Date: 2015-10-25 Impact factor: 4.191
Authors: Paul Glasziou; Douglas G Altman; Patrick Bossuyt; Isabelle Boutron; Mike Clarke; Steven Julious; Susan Michie; David Moher; Elizabeth Wager Journal: Lancet Date: 2014-01-08 Impact factor: 79.321
Authors: Julie Rouette; Jane Blazeby; Madeleine King; Melanie Calvert; Yingwei Peng; Ralph M Meyer; Jolie Ringash; Melanie Walker; Michael D Brundage Journal: Qual Life Res Date: 2014-11-29 Impact factor: 4.147
Authors: Fabio Efficace; Marc Jacobs; Andrea Pusic; Elfriede Greimel; Alfonso Piciocchi; Jacobien M Kieffer; Alexandra Gilbert; Peter Fayers; Jane Blazeby Journal: Eur J Cancer Date: 2014-05-10 Impact factor: 9.162
Authors: Michael Brundage; Jane Blazeby; Dennis Revicki; Brenda Bass; Henrica de Vet; Helen Duffy; Fabio Efficace; Madeleine King; Cindy L K Lam; David Moher; Jane Scott; Jeff Sloan; Claire Snyder; Susan Yount; Melanie Calvert Journal: Qual Life Res Date: 2012-09-18 Impact factor: 4.147
Authors: Rebecca Mercieca-Bebber; Michael J Palmer; Michael Brundage; Melanie Calvert; Martin R Stockler; Madeleine T King Journal: BMJ Open Date: 2016-06-15 Impact factor: 2.692
Authors: Eboni G Price-Haywood; Jewel Harden-Barrios; Christopher Carr; Laya Reddy; Lydia A Bazzano; Mieke L van Driel Journal: Qual Life Res Date: 2018-11-21 Impact factor: 4.147
Authors: Louis Garnier; Emilie Charton; Antoine Falcoz; Sophie Paget-Bailly; Dewi Vernerey; Marine Jary; François Ducray; Elsa Curtit Journal: Neurooncol Pract Date: 2020-11-11
Authors: Melanie Calvert; Madeleine King; Rebecca Mercieca-Bebber; Olalekan Aiyegbusi; Derek Kyte; Anita Slade; An-Wen Chan; E Basch; Jill Bell; Antonia Bennett; Vishal Bhatnagar; Jane Blazeby; Andrew Bottomley; Julia Brown; Michael Brundage; Lisa Campbell; Joseph C Cappelleri; Heather Draper; Amylou C Dueck; Carolyn Ells; Lori Frank; Robert M Golub; Ingolf Griebsch; Kirstie Haywood; Amanda Hunn; Bellinda King-Kallimanis; Laura Martin; Sandra Mitchell; Thomas Morel; Linda Nelson; Josephine Norquist; Daniel O'Connor; Michael Palmer; Donald Patrick; Gary Price; Antoine Regnault; Ameeta Retzer; Dennis Revicki; Jane Scott; Richard Stephens; Grace Turner; Antonia Valakas; Galina Velikova; Maria von Hildebrand; Anita Walker; Lari Wenzel Journal: BMJ Open Date: 2021-06-30 Impact factor: 2.692
Authors: Derek Kyte; Ameeta Retzer; Khaled Ahmed; Thomas Keeley; Jo Armes; Julia M Brown; Lynn Calman; Anna Gavin; Adam W Glaser; Diana M Greenfield; Anne Lanceley; Rachel M Taylor; Galina Velikova; Michael Brundage; Fabio Efficace; Rebecca Mercieca-Bebber; Madeleine T King; Grace Turner; Melanie Calvert Journal: J Natl Cancer Inst Date: 2019-11-01 Impact factor: 13.506
Authors: A L Slade; A Retzer; K Ahmed; D Kyte; T Keeley; J Armes; J M Brown; L Calman; A Gavin; A W Glaser; D M Greenfield; A Lanceley; R M Taylor; G Velikova; G Turner; M J Calvert Journal: Trials Date: 2021-04-26 Impact factor: 2.279
Authors: Mieke Van Hemelrijck; Francesco Sparano; Lisa Moris; Katharina Beyer; Francesco Cottone; Mirjam Sprangers; Fabio Efficace Journal: Cancer Med Date: 2020-04-25 Impact factor: 4.452